Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.88
+0.20005.43%
Post-market: 3.880.00000.00%16:00 EDT
Volume:227.33K
Turnover:872.10K
Market Cap:391.88M
PE:-9.02
High:3.97
Open:3.68
Low:3.58
Close:3.68
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.78
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.82
PE(LYR):-8.00

Loading ...

Company Profile

Company Name:
Galectin Therapeutics
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
9
Office Location:
4960 Peachtree Industrial Boulevard,Suite 240,Norcross,Georgia,United States
Zip Code:
30071
Fax:
- -
Introduction:
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Directors

Name
Position
Joel Lewis
Chief Executive Officer, President and Director
Richard E. Uihlein
Chairman and Independent Director
Benjamin S. Carson, Sr.
Independent Director
Elissa J. Schwartz
Independent Director
Gilbert F. Amelio
Independent Director
Gilbert S. Omenn
Independent Director
Harold H. Shlevin
Independent Director
Henry Brem
Independent Director
Kary Eldred
Independent Director
Kevin D. Freeman
Independent Director
Richard A. Zordani
Independent Director

Shareholders

Name
Position
Joel Lewis
Chief Executive Officer, President and Director
Jack W. Callicutt
Chief Financial Officer
Khurram Jamil
Chief Medical Officer